Are we sure that phase II is completed for TDM-105975?
The clinical trials gov website says it's still in the recruiting stage: https://clinicaltrials.gov/study/NCT05802173
TechnoDerma Medicines new small molecule - TDM-105795
- Thread starter nick123
- Start date
Are we sure that phase II is completed for TDM-105975?
The clinical trials gov website says it's still in the recruiting stage: https://clinicaltrials.gov/study/NCT05802173
Per someone in the trial, recruitment was complete a long time ago, and they are done now. Some companies just aren't timely with updates
Update regarding the phase 2a trials:
"Evaluation of efficacy by measurement of non-vellus Target Area Hair Count (TAHC) showed mean changes from baseline of 24.3 hairs with the high label strength (0.02%) and 20.3 hairs with the low label strength (0.0025%) topical solution, compared to 14.0 hairs with placebo in 1 cm2 test areas; randomization was 1:1:1 with 71 patients enrolled. Both label strengths of TDM-105795 were well tolerated with no material safety issues identified. Bioanalytical results show that once daily application of TDM-105795 topical solution at either dose produced extremely low to no systemic exposure."
Overall:
0.02% once daily - 24.3 TAHC (per cm2)
0.0025% once daily - 20.3 TAHC (per cm2)
Placebo - 14.0 TAHC (per cm2)
Both 0.02% and 0.002% once daily was well tolerated with no material safety issues and extremely low to no systemic exposure.
Source: https://www.prnewswire.com/news-rel...rowth-in-androgenetic-alopecia-302052631.html
"Evaluation of efficacy by measurement of non-vellus Target Area Hair Count (TAHC) showed mean changes from baseline of 24.3 hairs with the high label strength (0.02%) and 20.3 hairs with the low label strength (0.0025%) topical solution, compared to 14.0 hairs with placebo in 1 cm2 test areas; randomization was 1:1:1 with 71 patients enrolled. Both label strengths of TDM-105795 were well tolerated with no material safety issues identified. Bioanalytical results show that once daily application of TDM-105795 topical solution at either dose produced extremely low to no systemic exposure."
Overall:
0.02% once daily - 24.3 TAHC (per cm2)
0.0025% once daily - 20.3 TAHC (per cm2)
Placebo - 14.0 TAHC (per cm2)
Both 0.02% and 0.002% once daily was well tolerated with no material safety issues and extremely low to no systemic exposure.
Source: https://www.prnewswire.com/news-rel...rowth-in-androgenetic-alopecia-302052631.html
So, basically TechnoDerma gave better regrowth than HMI-115?
- Reaction score
- 984
Yes
That's impossible to know without comparing them head to head under the same conditions. The difference between them is too close to know which is more effective. TDM gained 6-10 hairs versus placebo. HMI-115 gained 14 hairs, but they had no placebo group. We will get a better comparison after they both run a longer placebo-controlled trial.
Last edited:
HMI-115 will have bigger advantage, because daily apply will be pain the *** for most of the people.
It will probably be more expensive though
- Reaction score
- 70
If you apply it once a day, it's not tedious at all, at least for me. It's all about results.
I think TDM (in comparison) will be cheaper. We'll see.
I think TDM (in comparison) will be cheaper. We'll see.
- Reaction score
- 4
Si realmente saliera sería muchísimo más barato, que no os quepa duda. HMI son anticuerpos monoclonales, son tratamientos muy muy caros.
Yes, it will be more expensive probably, but for young people it will be good solution.
At the very early stage of balding they can get 6 injections of HMI-115, stop balding, get some decent regrowth and keep their hair in next 5-7 years without bothering to apply daily, weekly or monthly topicals on their head to maintain results. In every 5-7 years you can go and take HMI-115 treatment to maintain the results. For bald people this is not ideal treatment, for much younger generation it can be.
Nobody knows how long you can maintain results with TechnoDerma when you will stop using it.
- Reaction score
- 2,705
Just get on HRT. How hard is that?